Mustang Bio Inc
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases. It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB-108 … Read more
Mustang Bio Inc (MBIO) - Net Assets
Latest net assets as of September 2025: $9.77 Million USD
Based on the latest financial reports, Mustang Bio Inc (MBIO) has net assets worth $9.77 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($19.36 Million) and total liabilities ($9.59 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $9.77 Million |
| % of Total Assets | 50.47% |
| Annual Growth Rate | N/A |
| 5-Year Change | -103.93% |
| 10-Year Change | N/A |
| Growth Volatility | 1081.56 |
Mustang Bio Inc - Net Assets Trend (2016–2024)
This chart illustrates how Mustang Bio Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Mustang Bio Inc (2016–2024)
The table below shows the annual net assets of Mustang Bio Inc from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-3.87 Million | -3248.78% |
| 2023-12-31 | $123.00K | -99.73% |
| 2022-12-31 | $46.27 Million | -58.83% |
| 2021-12-31 | $112.40 Million | +14.19% |
| 2020-12-31 | $98.44 Million | +90.57% |
| 2019-12-31 | $51.65 Million | +41.92% |
| 2018-12-31 | $36.40 Million | -39.17% |
| 2017-12-31 | $59.83 Million | +146.47% |
| 2016-12-31 | $24.28 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Mustang Bio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 39225700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | % |
| Other Comprehensive Income | $611.00K | % |
| Other Components | $392.23 Million | % |
| Total Equity | $-3.87 Million | 100.00% |
Mustang Bio Inc Competitors by Market Cap
The table below lists competitors of Mustang Bio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tarmat Limited
NSE:TARMAT
|
$4.36 Million |
|
ISCC FINTECH SPA
F:L7H
|
$4.36 Million |
|
TPI Composites Inc
NASDAQ:TPIC
|
$4.36 Million |
|
AYRO Inc
NASDAQ:AYRO
|
$4.36 Million |
|
CMO Public Company Limited
BK:CMO
|
$4.35 Million |
|
Sequa Petroleum NV
PA:MLSEQ
|
$4.35 Million |
|
Trastor Real Estate Investment Company SA
AT:TRASTOR
|
$4.35 Million |
|
PMVCD
PINK:PMVCD
|
$4.35 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mustang Bio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 123,000 to -3,873,000, a change of -3,996,000 (-3248.8%).
- Net loss of 15,752,000 reduced equity.
- Dividend payments of 611,000 reduced retained earnings.
- New share issuances of 9,149,000 increased equity.
- Other comprehensive income increased equity by 20,000.
- Other factors increased equity by 3,198,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-15.75 Million | -406.71% |
| Dividends Paid | $611.00K | -15.78% |
| Share Issuances | $9.15 Million | +236.23% |
| Other Comprehensive Income | $20.00K | +0.52% |
| Other Changes | $3.20 Million | +82.57% |
| Total Change | $- | -3248.78% |
Book Value vs Market Value Analysis
This analysis compares Mustang Bio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $-6.20 | $0.86 | x |
| 2016-12-31 | $13.88 | $0.86 | x |
| 2017-12-31 | $35.54 | $0.86 | x |
| 2018-12-31 | $20.26 | $0.86 | x |
| 2019-12-31 | $21.48 | $0.86 | x |
| 2020-12-31 | $28.08 | $0.86 | x |
| 2021-12-31 | $19.18 | $0.86 | x |
| 2022-12-31 | $6.71 | $0.86 | x |
| 2023-12-31 | $0.01 | $0.86 | x |
| 2024-12-31 | $-0.63 | $0.86 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mustang Bio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-4252.23%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.05 Million |
| 2016 | -52.13% | 0.00% | 0.00x | 1.13x | $-15.08 Million |
| 2017 | -52.29% | 0.00% | 0.00x | 1.06x | $-37.27 Million |
| 2018 | -84.25% | 0.00% | 0.00x | 1.17x | $-34.30 Million |
| 2019 | -93.23% | 0.00% | 0.00x | 1.42x | $-53.32 Million |
| 2020 | -60.97% | 0.00% | 0.00x | 1.12x | $-69.86 Million |
| 2021 | -59.05% | 0.00% | 0.00x | 1.11x | $-77.61 Million |
| 2022 | -167.54% | 0.00% | 0.00x | 2.00x | $-82.15 Million |
| 2023 | -41952.85% | 0.00% | 0.00x | 144.24x | $-51.61 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-15.36 Million |
Industry Comparison
This section compares Mustang Bio Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mustang Bio Inc (MBIO) | $9.77 Million | 0.00% | 0.98x | $4.36 Million |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |